Molecular Formula | C29H40N2O3
|
Molar Mass | 464.64 |
Density | 1.16±0.1 g/cm3(Predicted) |
Boling Point | 617.1±55.0 °C(Predicted) |
Water Solubility | Soluble in DMSO, ethanol, or DMF at approx. 0.5mg/ml. May require heating or overnight mixing. Insoluble in water |
Solubility | ethanol: 0.7 mg/mL |
Appearance | solid |
Color | off-white |
pKa | 10.69±0.40(Predicted) |
Storage Condition | Keep in dark place,Inert atmosphere,Room temperature |
Stability | Stable for 1 year from date of purchase as supplied. Use caution when storing DMSO solutions. Typically solutions in DMSO can be stored at -20°C for approximately 2 months. However, any solutions that |
Physical and Chemical Properties | Bioactive U73122 is a potent phospholipase C (PLC) inhibitor, which can reduce the increase of Ca2 + in platelets and neutrophils induced by agonists. U73122 was effective in inhibiting human 5-lipoxygenase (5-LO). |
In vitro study | U73122 significantly inhibits the aggregation of human platelets induced by various agonists, including collagen, thrombin, ADP, arachidonic acid, with an IC50 of 1-5 μm. Thrombin, or U-46619, dose-dependently inhibits C5a,FMLP by inhibiting phosphatidyl catalyzed by the soluble fraction of platelets [U-73122, PAF and LTB4 induced release of MPO and B12-BP from cytochalasin B- treated PMNs. IC50 values for MPO release were 60 (FMLP),110 (LTB4),115 (C5a) and 120 (PAF) nM; IC50 values for release B12-BP were 105 (FMLP),110 (LTB4),120 (C5a) and 140 (PAY) nM. U-73122 is also a potent inhibitor of superoxide anion production by C5a or FMLP-activated cytochalasin B- treated PMNs with IC50 of 160 and 300 nM, respectively. U-73122 also inhibited [Ca U73122 significantly inhibited recombinant human PLC-β2 with an IC50 of ~ 6 μm in FMLP-stimulated PMNs. U73122 had a weak effect on PLC-β1,PLC-β3, or PLC-β4. In human neutrophils, U73122 reduces interleukin-8 and leukotriene b4-induced Ca in undifferentiated NG108-15 cells, 1 μm U73122 blocks bradykinin (BK) the induced intracellular free Ca U73122 is a relatively specific inhibitor of G protein-mediated phospholipase C activation in pancreatic vesicles. U73122 inhibited the hydrolytic action of phosphatidylinositol (PI) on stimulation by Cholecystokinin (81%) or acetylcholine (73%) at a maximum concentration of 10 μm. In fura-2 loaded acini, U73122 (10 μm) inhibited high-concentration secretagogue-stimulated [Ca U73122 concentration-and time-dependently increased the activity of hPLCβ3 in the cell-free micelle system, with an up to 8-fold increase in enzyme activity, the EC50 was 13.6 μm. Activation of HPLC β3 by U73122 requires covalent modification of cysteine. U73122 (10 μm) also activates hPLCγ1(>10-fold) and hPLCβ2(~ 2-fold); Plc1 is not activated or inhibited. |
In vivo study | U73122 (30 mg/kg, I. P.) blocked the edema of hind paws 65% and 80% of rats after 1 hour and 3 hours of carrageenan treatment. In dogs, U73122 (0.1 mg/ml) inhibited carrageenan-induced accumulation of 65% of macrophages and 74% of lymphocytes into the subcutaneous compartment, respectively. U73122 (30 mg/kg, I. P.) completely inhibited LPS-induced macrophage and lymphocyte infiltration, as well as prostaglandin E2(80%) in a mouse peritonitis model, it also inhibited the mouse ear swelling induced by 12-o-tetradecyl-phorbol -13-acetate. |